MATINAS BIOPHARMA HOLDINGS, INC. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1f9623da-7c12-407b-a0f3-aef2c415ef94/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $1.1M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011493 |
| FY 2022 | $3.2M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-007726 |
| FY 2021 | $33.0k | 2021-01-01 – 2021-12-31 | evidence 0001493152-23-007726 |
| FY 2020 | $158.3k | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-006979 |
| FY 2019 | $89.8k | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-003558 |
| FY 2018 | $119.8k | 2018-01-01 – 2018-12-31 | evidence 0001493152-20-003558 |
| FY 2017 | $149.7k | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-003518 |
| FY 2016 | $0 | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-018184 |
| FY 2015 | $194.5k | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-091635 |
| FY 2014 | $0 | 2014-01-01 – 2014-12-31 | evidence 0001144204-16-091635 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
MATINAS BIOPHARMA HOLDINGS, INC. — all facts · Net Income · Operating Income